(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

UBS estimates that a 15% tariff on exports to the United States will require luxury brands on average to raise prices by ...

Anne Hoecker, Bain & Company's head of global technology practice, joins CNBC's 'Squawk on the Street' to discuss the growth ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

Bain & Co. is closing down its consultancy business in Johannesburg, likely bringing to an end a years-long battle to try and ...

South Africa’s National Treasury accused the Boston-based firm of engaging in “corrupt and fraudulent practices” related to a ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Bain shuts South Africa consultancy after state capture scandalJohannesburg office shifts to global services support ...

Bain & Co exits South Africa after Zondo fallout; Athol Trollip lays charges against Paul O’Sullivan amid a feud over ...